What are the most common compounded medications? Compounding pharmacy exists because patients do not come in standard formulations — and neither should their medications.
For the practicing clinician, the value of compounding is rarely theoretical. It shows up in the patient who cannot swallow a commercial capsule, the practice that needs a dosing strength the manufacturer stopped producing, or the clinic building a weight management program that requires a personalized therapeutic approach. In each of these situations, a licensed compounding pharmacy provides what commercial pharmaceutical manufacturing cannot: a medication made to specification, for a named patient, pursuant to a valid prescription from a licensed provider.
Understanding which medications are most commonly compounded — and why — gives providers a practical framework for knowing when to consider compounded formulations as part of their clinical toolkit. This guide covers the complete spectrum of commonly compounded medications, organized by therapeutic category, with clinical rationale for each.
What Are Compounded Medications?
Compounded medications are customized pharmaceutical preparations created by a licensed pharmacist based on a specific prescription from a licensed healthcare provider. Unlike commercially manufactured drugs — which are mass-produced in fixed doses, fixed delivery forms, and fixed excipient combinations — compounded medications are prepared patient-by-patient to meet precise clinical requirements.
The practice of pharmacy compounding is regulated at both federal and state levels. In the United States, most traditional compounding pharmacies operate as 503A facilities, meaning they prepare medications based on individual patient prescriptions and are regulated primarily by state boards of pharmacy. A smaller number of facilities operate as 503B outsourcing facilities, which are FDA-registered and may produce larger batches for licensed healthcare facilities under Current Good Manufacturing Practice (CGMP) standards.
Both sterile compounding and non-sterile compounding fall under this framework. Sterile preparations — including injectables, ophthalmic solutions, and certain infusions — must be prepared under USP Chapter 797 cleanroom standards. Non-sterile preparations — including creams, gels, capsules, and troches — are governed by USP Chapter 795.
According to the Alliance for Pharmacy Compounding 2025–2026 survey of more than 600 pharmacy compounding professionals across the United States, an estimated 1 to 3 percent of all U.S. prescriptions are compounded — but that percentage represents a substantial patient population whose clinical needs cannot be met by commercially available products. The median 503A compounding pharmacy dispenses approximately 350 compounded prescriptions per week, working with around 150 different prescribers.
The Most Common Compounded Medications by Category
1. Hormone Replacement Therapy (HRT) Compounds — The Most Frequently Compounded Category
Hormone replacement therapy consistently represents the single largest category of compounded medications. According to the APC 2025–2026 Snapshot of Pharmacy Compounding in America, hormone replacement therapy accounts for an average of 36 percent of all therapies dispensed by 503A compounding pharmacies — making it by far the most compounded therapeutic category in the United States.
The reasons are clinical and practical. Commercial hormone products are available in a limited range of doses, delivery systems, and hormone combinations. For the significant portion of patients who require customized hormone dosing — based on lab results, symptom response, and individual pharmacokinetics — compounded preparations provide the flexibility that manufactured products cannot.
Commonly compounded HRT preparations include:
Bioidentical Estrogen Formulations Compounded estradiol (E2), estriol (E3), and estrone (E1) preparations — individually or in combination — allow prescribers to specify exact concentrations, ratios, and delivery systems. Bi-est (estradiol/estriol) and Tri-est (all three) combinations are among the most frequently prescribed. Delivery forms include topical creams, gels, sublingual troches, vaginal suppositories, and injectable formulations for providers who offer pellet or injectable hormone protocols.
Progesterone Compounds Commercial oral progesterone (Prometrium) is the only FDA-approved oral progesterone product. Compounding allows progesterone to be formulated in transdermal cream, sublingual troche, vaginal suppository, and topical gel — delivery routes that may be preferable for specific patient populations or clinical applications. OBGYNs and women’s health practices are among the highest-volume users of compounded progesterone.
Testosterone Formulations Testosterone replacement therapy (TRT) for both male and female patients represents a major segment of HRT compounding. For male patients, compounded testosterone is available as topical cream or gel at clinician-specified concentrations, injectable suspension, and sublingual preparations. For female patients — who require much lower testosterone doses than those available in commercial male-formulated products — compounding is often the only practical option for precise low-dose testosterone therapy.
Thyroid Compounds Desiccated thyroid and compounded T3/T4 combinations are used in functional medicine and integrative endocrinology for patients who do not respond optimally to levothyroxine monotherapy. Compounding allows exact T3:T4 ratios based on individual patient thyroid panel results.
To learn more about sourcing bioidentical hormone compounds for your practice, see our hormone therapy compounding page.
2. Dermatology & Aesthetic Compounds
According to the APC 2025–2026 survey, dermatology medications represent approximately 8 percent of therapies dispensed by compounding pharmacies — the fourth most common category nationally, and one of the fastest-growing segments in aesthetic medicine.
Dermatology compounding is driven by the reality that commercial topical products are formulated for the general patient population. For dermatologists and aesthetic providers managing complex presentations — treatment-resistant acne, melasma in Fitzpatrick IV–VI skin types, post-procedure recovery — fixed commercial concentrations and delivery bases are frequently inadequate.
Commonly compounded dermatology medications include:
Tretinoin at Custom Concentrations Commercial tretinoin products are available at 0.025%, 0.05%, and 0.1%. Compounding allows concentrations from 0.01% for sensitive patients through 0.3% for advanced anti-aging or acne protocols, in prescriber-selected bases — a level of precision unavailable from any commercial manufacturer.
Modified Kligman’s Formula (Hyperpigmentation) The triple combination of hydroquinone, tretinoin, and a corticosteroid at clinician-specified percentages is the clinical standard for melasma management. No commercial product allows the prescriber to independently control all three components. Compounding makes this possible.
Topical Anesthetics for Aesthetic Procedures BLT cream (benzocaine, lidocaine, tetracaine) at provider-specified concentration ratios is used by aesthetic clinics and medical spas for pre-procedure numbing prior to laser treatments, microneedling, filler injections, and waxing. BLT cream is only available through a licensed compounding pharmacy with a valid provider prescription.
Kojic Acid, Azelaic Acid, and Brightening Combinations Combination brightening formulations — kojic acid with azelaic acid, niacinamide, or tranexamic acid — are not commercially available at therapeutic ratios. Compounding allows dermatologists to prescribe melanin-targeting combinations tailored to skin type and presentation.
See our complete guide to custom skincare formulations for dermatology practices for a full breakdown of available formulations.
3. Peptide Medications
Peptide compounding has grown rapidly as functional medicine, anti-aging medicine, and weight management practices expand their clinical protocols. Peptides are short chains of amino acids that function as biological signaling molecules — influencing growth hormone release, tissue repair, fat metabolism, immune regulation, and skin rejuvenation.
Compounded peptides are prepared as sterile injectable solutions by pharmacies holding appropriate sterile compounding licensure under USP Chapter 797. The prescription-based nature of peptide compounding — and the sterile preparation requirements — mean that not all compounding pharmacies can provide these formulations. Providers should verify their pharmacy partner’s sterile licensure before sourcing any injectable peptide compound.
Commonly compounded peptides include:
BPC-157 (Body Protection Compound) One of the most frequently requested peptides in clinical practice. BPC-157 is used in functional medicine and sports medicine contexts for musculoskeletal support, gut healing protocols, and tissue repair. Compounded as sterile injectable or occasionally as oral formulation.
Sermorelin, CJC-1295, and Ipamorelin Growth hormone secretagogue peptides used in anti-aging and performance medicine protocols. These peptides stimulate endogenous growth hormone release rather than providing exogenous GH — a clinical distinction that matters for both efficacy and regulatory positioning. Typically compounded as sterile injectables.
AOD-9604 A modified fragment of human growth hormone used in weight management-adjacent protocols. Compounded as sterile injectable.
GHK-Cu (Copper Peptide) Used in aesthetic dermatology and anti-aging protocols, including topical serums and some injectable preparations, for collagen support and skin rejuvenation.
For a clinical reference on peptide compounding, see our guide to peptide therapy for weight loss.
4. Weight Management Compounds
GLP-1 receptor agonists represented approximately 11 percent of therapies dispensed by compounding pharmacies according to the APC 2025–2026 survey — the third most common therapeutic category. However, the regulatory status of GLP-1 compounding has changed significantly in 2025–2026 and requires careful clinical and compliance attention.
GLP-1 Compounding — Current Status (2026)
The FDA resolved the semaglutide shortage in February 2025 and the tirzepatide shortage in late 2024. On April 30, 2026, the FDA proposed formally excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List, citing no clinical need for outsourcing facilities to compound these agents from bulk drug substances. This proposal closes the bulk compounding pathway for these agents under 503B.
Under 503A, patient-specific compounding of these agents remains a more restricted pathway — permissible where there is a documented clinical need for a formulation meaningfully different from the commercially available product (different route of administration, unique combination, or documented clinical necessity). Providers sourcing any GLP-1 compound in 2026 should confirm their pharmacy partner’s current compliance posture and verify that all compounding is conducted under a legally defensible 503A patient-specific rationale.
Other weight management compounds less affected by the GLP-1 regulatory changes include:
- MIC/LIPO injections (Methionine, Inositol, Choline combinations) for lipotropic weight management protocols
- B12 combination injectables for metabolic support in weight loss programs
- Phentermine compounded topical or specialized oral preparations for practices offering medically supervised weight programs
- Naltrexone/Bupropion combinations at custom doses for practices where commercial Contrave dosing is not optimal
5. Pain Management Compounds
Pain management represents one of the largest and most established segments of compounding pharmacy — accounting for approximately 31 percent of the global compounding market by therapeutic area, according to industry data.
The clinical rationale is powerful: chronic pain patients are highly heterogeneous in their medication response, tolerability, and delivery preferences. Compounded preparations allow prescribers to combine analgesic mechanisms, specify delivery routes, and avoid systemic side effects by delivering medication directly to the pain site.
Commonly compounded pain management medications include:
Transdermal Pain Creams Custom transdermal formulations combining agents such as ketamine, gabapentin, cyclobenzaprine, lidocaine, diclofenac, and baclofen at clinician-specified concentrations allow targeted delivery to affected areas. Transdermal delivery bypasses first-pass metabolism and reduces systemic side effect burden compared to oral pain medications — a meaningful advantage for patients with GI intolerance or complex polypharmacy.
Compounded Low-Dose Naltrexone (LDN) Standard commercial naltrexone is available at 50mg — far above the doses used in LDN protocols (1.5mg–4.5mg). Compounded LDN requires a licensed compounding pharmacy with non-sterile compounding capability and precise low-dose formulation expertise.
Compounded Ketamine Preparations Approximately 76 percent of compounding pharmacy survey respondents reported offering compounded ketamine, with the top formulations being sublingual (78%), nasal (71%), and transdermal (66%). Ketamine compounding for pain and mental health applications represents a rapidly growing segment, with sublingual and nasal formulations enabling outpatient administration protocols.
Custom Topical NSAID Combinations Diclofenac at concentrations above commercially available products, or combined with other agents in a single transdermal preparation, allows pain management practices to optimize anti-inflammatory topical therapy for specific musculoskeletal indications.
6. Men’s Health Compounds
Men’s health treatments account for approximately 7 percent of therapies dispensed by compounding pharmacies according to the APC 2025–2026 survey — the fifth most common compounded category nationally. This reflects the growing clinical infrastructure around men’s health optimization clinics and hormone-focused practices.
Commonly compounded men’s health medications include:
- Testosterone cypionate or enanthate injectable at provider-specified concentration in appropriate oil vehicle
- Clomiphene (Clomid) compounded capsules for HPG axis support in male patients
- Human chorionic gonadotropin (HCG) injectable for testicular support during TRT
- Tadalafil or Sildenafil compounded at custom doses in oral or sublingual formulations for ED protocols
- PT-141 (Bremelanotide) compounded injectable for sexual health indications
7. Pediatric Compounds
Pediatric medication compounding addresses a fundamental gap in commercial pharmaceutical manufacturing: most drugs are developed and tested in adult populations, and commercial formulations frequently do not exist in appropriate pediatric doses or delivery forms.
Common pediatric compounding applications include:
- Oral liquids at weight-appropriate doses from medications only commercially available in adult tablet form
- Flavored liquid formulations to improve pediatric medication adherence
- Allergen-free preparations — dye-free, preservative-free, gluten-free, lactose-free — for pediatric patients with sensitivities
- Transdermal pediatric formulations for children who cannot reliably take oral medication
- Custom-concentration pediatric antibiotics and antivirals during commercial drug shortages
8. Veterinary Compounds
Veterinary drugs represent approximately 14 percent of therapies dispensed by compounding pharmacies — the second most common category after HRT. This reflects the diversity of animal species requiring medication, the frequent unavailability of veterinary-specific commercial formulations, and the palatability challenges involved in medicating animals.
Compounded veterinary medications — including flavored oral liquids, transdermal ear gels for cats, and custom-dose injectables — represent a significant market segment that complements human compounding practice.
How Providers Source Compounded Medications
For clinicians looking to incorporate compounded medications into their practice — whether for HRT protocols, aesthetic procedures, peptide therapies, or pain management — the process begins with identifying a pharmacy partner that holds the appropriate credentials.
Key criteria for provider evaluation include:
Sterile Compounding Licensure — Required for all injectable formulations including peptides, HRT injectables, ketamine preparations, and aesthetic anesthetics. Verify USP Chapter 797 compliance and active state sterile compounding licensure.
Controlled Substance Authorization — Verify DEA registration covering the specific schedules relevant to your protocols.
State Pharmacy Licensing — Confirm the pharmacy holds active licensure in every state where your patients receive medications.
LegitScript Certification — The gold standard for pharmacy operational legitimacy, recognized by Google and Bing as third-party verification of legal compliance and transparency.
HIPAA-Compliant Prescription Processing — Essential for any practice sharing patient PHI with a pharmacy partner.
Why Emerald Compounding Pharmacy Serves Providers Across These Categories
Emerald Compounding Pharmacy, based in Tampa, Florida, is licensed, certified, and operationally equipped to serve providers across the full spectrum of common compounded medication categories — from hormone therapy and peptides to dermatology, aesthetic, and men’s health protocols.
Certifications, Accreditations & Compliance
Compounding Pharmacy License — Florida DOH License #PH35337 | Special Sterile Compounding Qualified Emerald holds active Florida Department of Health licensure with Special Sterile Compounding qualifications — authorizing preparation of all sterile injectable formulations including peptide compounds, HRT injectables, aesthetic anesthetics, and sterile dermatology preparations under USP Chapter 797 standards. License verification is publicly available through the Florida DOH MQA Search Services database.
Community Pharmacy License — Florida DOH License #PH35074 Active Florida DOH community pharmacy licensure, including full authorization to dispense Schedule II and III controlled substances — covering the complete range of controlled compounds used in HRT, pain management, and men’s health protocols.
DEA Controlled Substance Registration #FE4155974 — Schedules II through V Federal DEA registration covering Schedule II, IIN, III, IIIN, IV, and V. For providers whose compounding protocols include scheduled controlled substances across any therapeutic category, this registration confirms Emerald’s federal authorization to handle, prepare, and dispense those agents in compliance with DEA regulations.
LegitScript Certified Emerald is LegitScript Certified — one of a small number of compounding pharmacies in the United States to hold this designation. LegitScript certification verifies legal compliance, operational transparency, and adherence to safety standards, and is recognized by Google, Bing, and major payment platforms as a third-party credibility signal. It is not self-reported — it requires independent verification of the pharmacy’s licensing, operations, and compliance posture.
HIPAA Compliant All patient Protected Health Information shared through the prescription process is handled in full HIPAA compliance through Emerald’s secure provider portal and internal systems.
Pharmacy Technician Training Program — Florida DOH License #RTTP1477 Florida DOH authorization to operate an official pharmacy technician training program — reflecting the institutional expertise of Emerald’s compounding team.
Biomedical Waste Operating Permit #29-64-2899253 Active Florida DOH biomedical waste management authorization — evidence of compliant, regulated operations across all aspects of the pharmacy’s workflow.
For a complete listing of Emerald’s certifications and compliance documentation, visit our certifications page.
Emerald offers same-day shipping on prescriptions received before 2:00 PM EST, a secure HIPAA-compliant provider portal for prescription submission and order management, and direct pharmacist consultation for complex formulation or protocol questions.
Frequently Asked Questions About Common Compounded Medications
What are the most commonly compounded medications?
According to the Alliance for Pharmacy Compounding 2025–2026 national survey of over 600 compounding professionals, the top five compounded therapeutic categories in the United States are: hormone replacement therapy (36% of therapies dispensed), veterinary medications (14%), GLP-1 receptor agonists (11%), dermatology preparations (8%), and men’s health treatments (7%). Pediatric formulations, pain management compounds, and peptide medications are also among the most frequently compounded categories.
Why do providers prescribe compounded medications?
Providers prescribe compounded medications when commercially available products do not meet a patient’s specific clinical needs. Common reasons include the need for a custom dose or concentration not commercially available, a required delivery form different from what manufacturers produce, allergen or excipient elimination, combination therapies not available as commercial finished products, or continuity of care during commercial drug shortages.
Is a prescription required for all compounded medications?
Yes — without exception. Every compounded medication requires a valid prescription from a licensed healthcare provider naming a specific patient. Compounding pharmacies operating under 503A regulations cannot legally dispense compounded medications without a patient-specific prescription. This applies to all categories of compounded medications, including topical preparations, injectables, capsules, and troches.
What is the difference between sterile and non-sterile compounded medications?
Sterile compounded medications — including all injectables, ophthalmic preparations, and certain infusions — must be prepared in a licensed sterile compounding facility compliant with USP Chapter 797 standards, which mandate cleanroom infrastructure, environmental monitoring, and sterility testing. Non-sterile compounded medications — including topical creams, oral capsules, and troches — are prepared under USP Chapter 795 standards, which govern non-sterile compounding quality and beyond-use dating. For more, see our guide on the difference between sterile and non-sterile compounding.
Can a compounding pharmacy compound hormone replacement therapy?
Yes. Hormone replacement therapy is the most commonly compounded category of medication in the United States. A licensed 503A compounding pharmacy can prepare bioidentical estrogen, progesterone, testosterone, and thyroid compounds at clinician-specified concentrations and in prescriber-selected delivery forms — including topical creams, injectable suspensions, sublingual troches, and vaginal preparations — pursuant to a valid prescription from a licensed provider.
How do I know if a compounding pharmacy is legitimate?
Verify the pharmacy’s credentials directly through regulatory databases. State pharmacy licenses can be confirmed through each state’s Department of Health MQA verification portal. DEA registration can be verified through the DEA’s online system. LegitScript certification status can be confirmed at legitscript.com. For Florida pharmacies, Emerald Compounding Pharmacy’s licenses (#PH35337 and #PH35074) are publicly verifiable through the Florida DOH MQA database.
What peptides are most commonly compounded?
Commonly compounded peptides in clinical practice include BPC-157 for musculoskeletal and gut healing protocols, sermorelin and CJC-1295/Ipamorelin for growth hormone secretagogue therapy, AOD-9604 for metabolic support, and GHK-Cu for aesthetic skin applications. All peptide injectables require a licensed sterile compounding pharmacy compliant with USP Chapter 797, and all require a valid prescription from a licensed provider.
How do providers partner with a compounding pharmacy?
Providers register with a compounding pharmacy through a credentialing process that involves submission of prescriber license information and verification of active licensure. Following approval, providers access a secure portal for submitting patient-specific prescriptions and managing orders. Emerald Compounding Pharmacy’s provider registration typically takes 24 to 48 hours from application submission.
Partner with Emerald for Your Compounding Pharmacy Needs
Emerald Compounding Pharmacy provides licensed, credentialed, sterile-qualified compounding across the full spectrum of commonly prescribed compound categories — hormone therapy, dermatology, peptides, pain management, men’s health, and weight management protocols that fall within current regulatory frameworks.
- ✔ Florida DOH Licensed — Special Sterile Compounding Qualified (#PH35337)
- ✔ DEA Registered — Schedules II through V (#FE4155974)
- ✔ LegitScript Certified
- ✔ HIPAA Compliant
- ✔ Same-day shipping — prescriptions received before 2:00 PM EST
- ✔ Secure provider portal — prescription, tracking, consultation
- ✔ No minimum order volume
Become a Provider → Call: (877) 443-7711 | Tampa, FL
All compounded medications require a valid prescription from a licensed healthcare provider. Compounded medications are not FDA-approved finished drug products. Emerald Compounding Pharmacy operates in full compliance with Florida Department of Health and federal DEA regulations. Providers should verify current FDA regulatory guidance regarding GLP-1 compounding before prescribing.
